Abstract:MAIN POINTS: • By expressing mutant fused in sarcoma (FUS) protein in mouse spinal cord astrocytes, we observe pathogenic changes leading to motor abnormalities. • We identify TNFα as a bona fide source of toxicity and demonstrate the feasibility of targeting TNFα therapeutically. Genetic mutations that cause amyotrophic lateral sclerosis (ALS), a progressively lethal motor neuron disease, are commonly found in ubiquitously expressed genes. In addition to direct defects within motor neurons, growing evidence suggests that dysfunction of non‐neuronal cells is also an important driver of disease. Previously, we demonstrated that mutations in DNA/RNA binding protein fused in sarcoma (FUS) induce neurotoxic phenotypes in astrocytes in vitro, via activation of the NF‐κB pathway and release of pro‐inflammatory cytokine TNFα. Here, we developed an intraspinal cord injection model to test whether astrocyte‐specific expression of ALS‐causative FUSR521G variant (mtFUS) causes neuronal damage in vivo. We show that restricted expression of mtFUS in astrocytes is sufficient to induce death of spinal motor neurons leading to motor deficits through upregulation of TNFα. We further demonstrate that TNFα is a key toxic molecule as expression of mtFUS in TNFα knockout animals does not induce pathogenic changes. Accordingly, in mtFUS‐transduced animals, administration of TNFα neutralizing antibodies prevents neurodegeneration and motor dysfunction. Together, these studies strengthen evidence that astrocytes contribute to disease in ALS and establish, for the first time, that FUS‐ALS astrocytes induce pathogenic changes to motor neurons in vivo. Our work identifies TNFα as the critical driver of mtFUS‐astrocytic toxicity and demonstrates therapeutic success of targeting TNFα to attenuate motor neuron dysfunction and death. Ultimately, through defining and subsequently targeting this toxic mechanism, we provide a viable FUS‐ALS specific therapeutic strategy, which may also be applicable to sporadic ALS where FUS activity and cellular localization are frequently perturbed.

FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms

TNFα prevents FGF4-mediated rescue of astrocyte dysfunction and reactivity in human ALS models

Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology

Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity

Neuromuscular dysfunction in patient-derived FUS -ALS iPSC model via axonal downregulation of neuromuscular junction proteins

Why should we care about astrocytes in a motor neuron disease?

Astrocyte-Neuron Interactions Contributing to Amyotrophic Lateral Sclerosis Progression

Early nuclear phenotypes and reactive transformation in human iPSC-derived astrocytes from ALS patients with SOD1 mutations

Human iPSC co-culture model to investigate the interaction between microglia and motor neurons

Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs

Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis‐linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice

Recent insights from human induced pluripotent stem cell models into the role of microglia in amyotrophic lateral sclerosis

ALS, a cellular whodunit on motor neuron degeneration

Generation of an Open-Access Patient-Derived iPSC Biobank for Amyotrophic Lateral Sclerosis Disease Modelling

Disruption of MAM integrity in mutant FUS oligodendroglial progenitors from hiPSCs

The Key Role of Astrocytes in Amyotrophic Lateral Sclerosis and Their Commitment to Glutamate Excitotoxicity

Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates

Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons

Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia

Inflammatory cytokines disrupt astrocyte exosomal HepaCAM-mediated protection against neuronal excitotoxicity in the SOD1G93A ALS model

Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability